Clinical trial · Observational
Establishment of Fibroid Tissue Bank
Establishment of a Fibroid Tissue Bank
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect information and tissue samples from women with uterine fibroids. The samples will be used to study genes, proteins and other substances in order to better understand the disease process and improve fertility and reproductive health. Women who are scheduled to undergo hysterectomy, myomectomy or other surgery due to uterine fibroids or to an unusual variant of fibroid disease, such as HLRCC or benign metastasizing leiomyomatosis, may be eligible for this study. Tissue samples are collected from participants during surgery. The samples are coded and catalogued for research use. Data collected regarding the surgery include the sample location, surgery type, reason for surgery and the primary and secondary diagnoses. Additional data collected about the participant include date of birth, race, ethnicity, weight, height, smoking status, information about menstrual cycles, medications and family history.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (0)
Data not yet available
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
* INCLUSION CRITERIA: * Women aged 21-80 with uterine fibroids * Medically indicated hysterectomy, myomectomy or other surgery for uterine fibroids. * Samples from patients with unusual variants of fibroid disease (HLRCC, benign metastasizing leiomyomatosis) will be included. These samples may possibly not arise from the uterus proper, as the leiomyoma may have become located elsewhere in the body. EXCLUSION CRITERIA: * Inability to give consent or understand the consent forms. * HIV-infected tissues will be excluded due to concern of equipment contamination. * Hepatitis-infected tissues will be excluded due to concern of equipment contamination.
References
Publications (3)
- BACKGROUNDMarshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, Willett WC, Hunter DJ. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997 Dec;90(6):967-73. doi: 10.1016/s0029-7844(97)00534-6. PMID 9397113
- BACKGROUNDLepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, Wilcox LS. Hysterectomy surveillance--United States, 1980-1993. MMWR CDC Surveill Summ. 1997 Aug 8;46(4):1-15. PMID 9259214
- BACKGROUNDPayson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am. 2006 Mar;33(1):1-11. doi: 10.1016/j.ogc.2005.12.004. PMID 16504803